Heart Failure Prognostic Score (Simplified)

Enter clinical and laboratory parameters to estimate short-term survival probabilities. Use for counseling and risk stratification alongside comprehensive clinical assessment.

Provide all clinical and laboratory inputs to calculate the survival estimate.

How to Use This Calculator

1

Collect up-to-date clinical data

Use recent labs, vitals, and echocardiography to ensure accuracy.

2

Enter guideline-directed therapy status

Note beta-blocker, RAAS inhibition, and device therapy, as these improve prognosis and reduce score.

3

Discuss results with patients

Use survival estimates to contextualise goals of care, lifestyle adjustments, and advanced therapy evaluation.

Formula

This simplified score sums weighted contributions from age, sex, NYHA class, ejection fraction, systolic blood pressure, sodium, creatinine, and adjusts for guideline-directed therapies. It approximates risk stratification published in the MAGGIC and Seattle Heart Failure models but is not a direct replacement.

Full Description

Prognostication in heart failure integrates demographic factors, functional class, ventricular function, haemodynamics, biomarkers, and evidence- based therapies. This tool synthesises key elements into a pragmatic score for quick counselling. For transplant or LVAD referrals, use validated instruments such as the Seattle Heart Failure Model or MAGGIC calculator alongside cardiopulmonary exercise testing and biomarker assessment.

Frequently Asked Questions

How does this differ from the Seattle Heart Failure Model?

The Seattle model uses detailed medication dosing, lab values, and device status to generate survival curves. This simplified score provides a quick approximation when full inputs are unavailable.

Can I use this for HFpEF?

Yes, but prognostication may differ. HFpEF often has higher survival; interpret with clinical judgement and consider additional markers (BNP, comorbidities).

Does adding CRT/ICD automatically improve prognosis?

Device therapy can improve survival when guideline criteria are met. Ensure appropriate patient selection and ongoing follow-up.

How frequently should I reassess?

Re-evaluate every 6–12 months or sooner if there are major clinical changes, hospitalisations, or therapy adjustments.